Recombinant rhesus monkey interleukin-3 (IL-3) was administered to normal rhesus monkeys in graded doses ranging from 3 to 30 pglkgld subcutaneously for 30 consecutive days or given as a continuous intravenous infusion at a dose of 30 pglkgld for 16 days. After a lag phase of about 1 week, a highly increased, dose-dependent production of bone marrow-derived blood cells was observed, preceded by amplification of bone marrow hematopoietic progenitor , also termed multilineage col-
complete its deve10pment.I~ As an alternative hypothesis we proposed the limited effects of human IL-3 in Macaca species to be in part attributable to its species specificity. Hence, we isolated the gene encoding rhesus monkey IL-3 (Rh-IL-3). 22 The Rh-IL-3 gene encodes a mature protein of 124 amino acids that lacks 9 C-terminal amino acids of human IL-3 and differs in 23 amino acids from the remaining mature human IL-3. Comparison of the coding DNA sequences of Rh-IL-3 with those of mice,2 rats,23 gibbons," and humans6*I8 showed a high rate of nonsynonymous nucleotide substitutions, which provides an explanation for the species specificity encountered for IL-3. 22 Here we report the multilineage effects of homologous IL-3 in rhesus monkeys.
MATERIALS AND METHODS

Monkeys.
IL-3.
Young adult male monkeys (Macaca mulatta) with a body weight of 3 to 4 kg were used throughout this study.
Rh-IL-3, expressed and excreted by B licheniformis. was purified to homogeneity as described." Its specific activity as tested on the basis of colony formation by purified Rhesus monkey bone marrow cells was about IO6 U/mg protein.
For the monkey receiving IL-3 intravenously (IV), a small miniature infusion pump (Dahedi Elektroniks, Maarssen, Holland) was connected to a Port-a-Cath system 427 CS (Pharmacia), subcutaneously implanted and entering a jugular vein; IL-3 infusion. the insulin pump was hidden in an especially designed jacket to prevent destruction and IL-3 was renewed every day.
Bone marrow was sampled weekly by pediatric spinal needle aspirates less than 0.5 mL from the shafts of humeri.
Cell counts. Peripheral blood red (RBCs) and white blood cells (WBCs), as well as bone marrow cellularity, were determined by a Baker Hematology Series 7000 automated cell counter. The differential of the WBCs was determined by standard counting after MayGriinwald-Giemsa staining. Reticulocytes were determined by staining of blood samples with brilliant cresyl blue and adjusted to absolute numbers based on the erythrocyte counts. Thrombocytes were determined by a Baker Hematology Series 810 platelet analyzer. CDl1 b, CD4, and CD8 positive cells were determined by a FACScan (Becton Dickinson); the monoclonals used, MOl,Z4 L e~3 a , *~ and L e~2 a ;~ respectively, were obtained from Becton Dickinson.
GM colony-forming units (GM-CFU) were detected in methylcellulose cultures2' stimulated with recombinant human GM-CSF (Glaxo, Geneva, Switzerland). The frequency of burst-forming units-erythroid (BFU-E) was measured in methylcellulose cultures stimulated with Rh-IL-3 and recombinant human erythropoietin (Eprex, Cilag, Herentals, Belgium).
Histamine concentrations were determined by an automated continuous flow fluorometric analysis? ' Normal values were independently determined on blood samples from at least 15 sex-and age-matched rhesus monkeys. In case of bone marrow and peripheral blood progenitor cells, the normal values included simultaneous serial measurements of three control monkeys as well as pretreatment values of IL-3-treated monkeys to a total of at least 30 data points; normal values were expressed as mean + standard error of the mean. 
RESULTS
Rh-IL-3 was administered to rhesus monkeys in doses ranging from 3 to 30 pg/kg/d subcutaneously during 30 consecutive days to test its in vivo effects. One monkey received a continuous IV infusion at the highest dose used as a pilot experiment for comparison of subcutaneous versus IV routes of administration, which was discontinued because of severity of side effects after 16 consecutive days. After a lag phase of 1 week, a strong dose-dependent effect on the numbers of nucleated blood cells, including normoblasts, was noted (Fig 1) . Analysis of WBCs showed increases in numbers of eosinophilic and neutrophilic granulocytes and the appearance of large numbers of cells designated as atypical (basophilic) granulocytes, reported earlier.19-21 Accordingly, intracellular histamine levels of peripheral blood cells increased directly proportional to the numbers of these atypical basophils ( Table 1 Peripheral blood cells were also monitored by measuring the frequency of cells with the myeloid differentiation antigen CD 1 1 b versus the number of T lymphocytes as characterized by CD4/CD8 antigens. Together these markers identify the vast majority of WBCs. CDl l b positive cells, including atypical basophilic granulocytes, showed an IL-3 dosedependent increase, whereas the T-lymphocyte numbers were not appreciably influenced by IL-3. In two monkeys that received 3 or 10 pg/kg/d, respectively, T lymphocytes were measured every 3 days during IL-3 treatment; peripheral blood T cells were stable at a mean value of 3.3 + 1.5 x 109/L, not different from simultaneously determined normal values.
The RBC lineage was strongly stimulated by IL-3. More than sixfold increases of reticulocyte numbers were observed in the monkeys that received 10 or 30 pg/kg/d (Table 1) . Normoblast numbers rose to 109/L in the recipient of 30 pg/kg/d subcutaneously and up to 18 x 109/L in the monkey that received a continuous infusion of 30 pg/kg/d (Fig 1) . The reticulocytosis did not translate into an increase in RBC numbers, most likely due to the frequent blood and bone marrow punctures for analyses. In addition, vast numbers of circulating normoblasts may also point to ineffective erythropoiesis, suggesting a possible lack of erythropoietin in levels proportional to those of IL-3.
Bone marrow was punctured weekly as specified in Table   2o (Fig 2) . The frequency of in vitro detected immature colony-forming hematopoietic progenitor cells GM-CFU and RFU-E increased as well throughout the treatment with IL-3. An illustrative example was provided by the monkey that received Rh-IL-3 IV. In this animal the progenitor cell numbers had increased on the seventh day of IL-3 treatment to 2.5 x IO" GM-CFU/mL punctate from a pretreatment number of 16 x lo3 GM-CFU/mL and to 3 x lo5 BFU-E/mL from 8 x 10' BFU-E/mL. Because peripheral blood counts during the first week of IL-3 administration did not show major changes (Fig l) , it is concluded that IL-3 initiated production of blood cells is preceded by amplification of immature bone marrow hematopoietic progenitor cells. In the same animal, the peripheral blood GM-CFU increased from 10/mL pretreatment to 0.8 x 103/mL after 14 days of IL-3 administration without an appreciable change during the first week.
The thrombocyte response to administration of Rh-IL-3 showed a peculiar dose dependence. At lower doses, a clear thrombocytosis was observed, which lasted for 2 weeks after discontinuation (Fig 3) . The monkeys that received 3 pg/ kg/d had mean peak thrombocyte counts of 618 x 109/L, starting from a mean pretreatment value of 377 x 1 0 9 /~, while those receiving 10 pg/kg/d increased from a mean of 285 x 109/L pretreatment to a maximum level of 580 x 109/L. The monkeys that received IL-3 in a dose of 30 pg/kg/d developed profound thrombopenia. Because all bone marrow preparations showed active megakaryocytopoiesis (eg, Fig 2) and shift platelets were abundant (data not shown), it was concluded that the thrombocytopenia reflected an increased consumption rather than decreased production.
Dose-related side effects (Table 3) included urticaria starting around day 10 of treatment, prominent axillary and inguinal lymph nodes from day 20 onward, and at high IL-3 doses facial and scrotal edema starting in the third week of treatment. The skin lesions were most numerous and prominent in monkeys that received 30 pg/kg/d IL-3. Histologically (Fig 4) , skin lesions were characterized by (1) marked perivascular accumulation of neutrophils, eosinophils, and most predominant by toluidine blue staining (not shown), mast cells; (2) widespread endothelial destruction; (3) marked superficial dermal edema; and (4) hemorrhage in most severely affected sites. Thrombocytopenia was coincident with vasculitis and hemorrhage in the generalized skin lesions of the monkeys administered IL-3 in high doses. Withdrawal of IL-3 not only prompted spontaneous resolution of skin lesions, but also of thrombocytopenia and other side effects without any sequeles within 2 to 4 days.
DISCUSSION
The results presented here demonstrate that in vivo administration of homologous IL-3 to rhesus monkeys resulted in a dose-dependent stimulation of the production of all bone marrow-derived cell lineages. In line with existing in vitro data and strongly supported by bone marrow analyses, this may be simply explained by increased production of progenitor cells from developmentally early, multipotential bone marrow cells resulting in augmented production of all bone marrow-derived blood cell lineages. Characteristically, a peripheral blood T-lymphocyte response was absent. The magnitude of the IL-3 responses described here are comparable with those seen after administration of murine recombinant IL-3 to or to the myeloproliferative disorder observed after retrovirus-mediated transfer and expression of the mouse IL-3 gene in mouse hematopoietic cells. 31 Among the hematopoietic growth factors, human IL-3 is the most rapid evolutionary divergent." Our present data with homologous Rh-IL-3 convincingly demonstrate that the results of in vivo studies on human IL-3 in nonhuman primates1'''' have suffered from the considerable species specificity of IL-3 and are not representative of its full potential.
We predict that many of the effects of IL-3 can be selectively amplified if combined with lineage-specific growth factors, such as erythropoietin for RBCs and G-CSF, M-CSF, 
